Table 5.
EACA (n = 91) |
Placebo (n = 91) |
P Value | |
---|---|---|---|
Potential complications of transfusion - no. (%) | |||
Wound infection | 0 | 0 | -- |
Nosocomial pneumonia | 1 (1.1) | 2 (2.2) | 0.56 |
Central venous line infection | 0 | 0 | -- |
Urinary tract infection | 1 (1.1) | 1 (1.1) | 1.00 |
Any infectious complication | 2 (2.2) | 3 (3.3) | 0.65 |
Potential complications of EACA - no. (%) | |||
Deep venous thrombosis | 0 | 2 (2.2) | 0.16 |
Cerebral infarction/ TIA | 0 | 1 (1.1) | 0.32 |
Myocardial infarction | 0 | 0 | -- |
Pulmonary embolism | 1 (1.1) | 3 (3.3) | 0.31 |
Acute renal failure | 1 (1.1) | 1 (1.1) | 1.00 |
Any thrombotic complication | 2 (2.2) | 6 (6.6) | 0.15 |
Potential surgical complications - no. (%) | |||
Reoperation due to bleeding | 0 | 2 (2.2) | 0.16 |
Outcomes - no. (%) | |||
In-hospital mortality | 0 | 1 (1.1) | 0.32 |
ICU length of stay - days | 1.8 ± 1.6 | 2.8 ± 4.6 | 0.04 |
Hospital length of stay - days | 8.5 ± 3.9 | 9.5 ± 8.6 | 0.32 |
Total hospital charges - dollars | 62,344 ± 27,497 | 68,670 ± 32,141 | 0.16 |
P values determined by Fisher’s exact test, two-sample t-test with unequal variances or Mann-Whitney rank-sum test as appropriate. Plus-minus values are mean ± SD. TIA is transient ischemic attack. ICU is intensive care unit. There were no differences in the incidence of clinically identified infections or thromboembolic complications. ICU LOS in the EACA group was significantly less, however, in-hospital LOS and charges were similar between the groups.